Candel Therapeutics, Inc.

Historical 13F Holders

Symbol
CADL
CUSIP
137404109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 137404109 since 12/18/2024, newest first.

Filer % of Class Filed
BlackRock, Inc. 13G 6.6% 7/27/2026
Event 6/30/2026
RTW Investments, LP 13G
8.8% 5/15/2026
Event 3/31/2026
BlackRock, Inc. 13G/A Amendment 1 4.2% 4/27/2026
Event 3/31/2026
Paul B Manning 13D/A Amendment 1
7.9% 3/18/2026
Event 12/16/2024
BlackRock, Inc. 13G 5.2% 1/21/2026
Event 12/31/2025
Acorn Bioventures, L.P. 13G
5.2% 6/30/2025
Event 6/25/2025
Baker Bros. Advisors LP 13G/A Amendment 1
4.99% 5/15/2025
Event 3/31/2025
Northpond Ventures, LP 13G/A Amendment 1
0% 2/14/2025
Event 12/31/2024
Baker Bros. Advisors LP 13G
6.8% 2/14/2025
Event 12/31/2024
CVI Investments, Inc. 13G/A Amendment 1
0% 2/7/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 1
15.0% 2/7/2025
Event 1/31/2025
FMR LLC 13G
9.3% 2/7/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 10 301 k $3.14 M
2026 Q2 145 50.4 M $520 M
2026 Q1 119 43.4 M $213 M
2025 Q4 91 23.6 M $134 M
2025 Q3 87 22.7 M $116 M
2025 Q2 85 23.1 M $117 M
2025 Q1 89 21.2 M $120 M
2024 Q4 83 20.0 M $173 M
2024 Q3 59 6.70 M $46.4 M
2024 Q2 52 6.00 M $37.2 M
2024 Q1 22 3.78 M $5.97 M
2023 Q4 24 4.03 M $5.92 M
2023 Q3 21 5.26 M $4.86 M
2023 Q2 21 5.37 M $6.77 M
2023 Q1 22 5.48 M $7.44 M
2022 Q4 23 5.45 M $9.75 M
2022 Q3 27 6.09 M $19.1 M
2022 Q2 24 6.35 M $20.6 M
2022 Q1 24 6.67 M $34.0 M
2021 Q4 21 6.95 M $54.4 M
2021 Q3 13 4.88 M $52.9 M